297 related articles for article (PubMed ID: 21876459)
1. Immunohistochemical expression of VEGF, HIF1-a, and PlGF in malignant melanomas and dysplastic nevi.
Konstantina A; Lazaris AC; Ioannidis E; Liossi A; Aroni K
Melanoma Res; 2011 Oct; 21(5):389-94. PubMed ID: 21876459
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical expression of vascular endothelial growth factor (VEGF) and C-KIT in cutaneous melanocytic lesions.
Stefanou D; Batistatou A; Zioga A; Arkoumani E; Papachristou DJ; Agnantis NJ
Int J Surg Pathol; 2004 Apr; 12(2):133-8. PubMed ID: 15173918
[TBL] [Abstract][Full Text] [Related]
4. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
5. Association of vascular endothelial growth factor expression with patohistological parameters of cutaneous melanoma.
Gacević M; Jović M; Zolotarevski L; Stanojević I; Novaković M; Miller K; Šuljagić V; Mijušković Ž; Vojvodić D
Vojnosanit Pregl; 2016 May; 73(5):449-57. PubMed ID: 27430109
[TBL] [Abstract][Full Text] [Related]
6. Expression of insulin-like growth factor-binding protein 2 in melanocytic lesions.
Wang H; Shen SS; Wang H; Diwan AH; Zhang W; Fuller GN; Prieto VG
J Cutan Pathol; 2003 Nov; 30(10):599-605. PubMed ID: 14744083
[TBL] [Abstract][Full Text] [Related]
7. Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions.
Miracco C; Cevenini G; Franchi A; Luzi P; Cosci E; Mourmouras V; Monciatti I; Mannucci S; Biagioli M; Toscano M; Moretti D; Lio R; Massi D
Hum Pathol; 2010 Apr; 41(4):503-12. PubMed ID: 20004946
[TBL] [Abstract][Full Text] [Related]
8. Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression.
Einspahr JG; Thomas TL; Saboda K; Nickolof BJ; Warneke J; Curiel-Lewandrowski C; Ranger-Moore J; Duckett L; Bangert J; Fruehauf JP; Alberts DS
Cancer; 2007 Dec; 110(11):2519-27. PubMed ID: 17932890
[TBL] [Abstract][Full Text] [Related]
9. Cyclin D1 and D3 expression in melanocytic skin lesions.
Alekseenko A; Wojas-Pelc A; Lis GJ; Furgał-Borzych A; Surówka G; Litwin JA
Arch Dermatol Res; 2010 Sep; 302(7):545-50. PubMed ID: 20496072
[TBL] [Abstract][Full Text] [Related]
10. Different patterns of expression of the erbB family of receptor tyrosine kinases in common nevi, dysplastic nevi, and primary malignant melanomas: an immunohistochemical study.
Feinmesser M; Veltman V; Morgenstern S; Tobar A; Gutman H; Kaganovsky E; Tzabari C; Sulkes J; Okon E
Am J Dermatopathol; 2010 Oct; 32(7):665-75. PubMed ID: 20559114
[TBL] [Abstract][Full Text] [Related]
11. Expression of the embryonic morphogen Nodal in cutaneous melanocytic lesions.
Yu L; Harms PW; Pouryazdanparast P; Kim DS; Ma L; Fullen DR
Mod Pathol; 2010 Sep; 23(9):1209-14. PubMed ID: 20495543
[TBL] [Abstract][Full Text] [Related]
12. The role of vascular endothelial growth factors and their receptors in malignant melanomas.
Brychtova S; Bezdekova M; Brychta T; Tichy M
Neoplasma; 2008; 55(4):273-9. PubMed ID: 18505336
[TBL] [Abstract][Full Text] [Related]
13. TSLC1 expression discriminates cutaneous melanomas from dysplastic nevi.
You Y; Wang SH; Zhang JF; Zheng SY
Melanoma Res; 2012 Dec; 22(6):430-5. PubMed ID: 23047161
[TBL] [Abstract][Full Text] [Related]
14. IMP-3 EXPRESSION IN BENIGN MELANOCYTIC NEVI, DYSPLASTIC NEVI AND MALIGNANT MELANOMA: PRELIMINARY FINDINGS IN BULGARIAN PATIENTS.
Chokoeva AA; Ananiev J; Wollina U; Tana C; Lotti T; Cardoso JC; Tchernev G
J Biol Regul Homeost Agents; 2015; 29(3):695-9. PubMed ID: 26403409
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of microtubule-associated protein 2 in melanocytic skin lesions.
Gambichler T; Rotterdam S; Radkowski K; Altmeyer P; Kreuter A
Am J Clin Pathol; 2009 May; 131(5):710-4. PubMed ID: 19369632
[TBL] [Abstract][Full Text] [Related]
16. Oestrogen receptor-beta expression in melanocytic lesions.
Schmidt AN; Nanney LB; Boyd AS; King LE; Ellis DL
Exp Dermatol; 2006 Dec; 15(12):971-80. PubMed ID: 17083364
[TBL] [Abstract][Full Text] [Related]
17. Absence of estrogen receptors in dysplastic nevi and malignant melanoma.
Lecavalier MA; From L; Gaid N
J Am Acad Dermatol; 1990 Aug; 23(2 Pt 1):242-6. PubMed ID: 2212119
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor expression in malignant melanoma: prognostic versus diagnostic usefulness.
Bayer-Garner IB; Hough AJ; Smoller BR
Mod Pathol; 1999 Aug; 12(8):770-4. PubMed ID: 10463478
[TBL] [Abstract][Full Text] [Related]
19. Assessment of vascularity in common blue nevi, small/medium congenital nevocellular, common and dysplastic acquired melanocytic nevi and melanomas: a comparative study.
Ioannidis EN; Aroni K; Kavantzas N
Am J Dermatopathol; 2014 Mar; 36(3):217-22. PubMed ID: 24067800
[TBL] [Abstract][Full Text] [Related]
20. Phosphoinositide 3-kinase is not overexpressed in melanocytic lesions.
Singh RS; Diwan AH; Zhang PS; Prieto VG
J Cutan Pathol; 2007 Mar; 34(3):220-5. PubMed ID: 17302605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]